Inventiva S.A. Sponsored ADR (NASDAQ:IVA – Get Free Report) shares shot up 10.1% during mid-day trading on Thursday . The stock traded as high as $4.25 and last traded at $4.4490. 345,206 shares were traded during trading, a decline of 19% from the average session volume of 426,642 shares. The stock had previously closed at $4.04.
Analyst Upgrades and Downgrades
Several brokerages recently issued reports on IVA. Wall Street Zen lowered Inventiva from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. Truist Financial began coverage on Inventiva in a research note on Thursday, March 19th. They set a “buy” rating and a $13.00 price target on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Inventiva in a research note on Tuesday, April 21st. Three analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $16.56.
View Our Latest Analysis on IVA
Inventiva Stock Down 4.7%
Inventiva (NASDAQ:IVA – Get Free Report) last released its quarterly earnings data on Sunday, February 15th. The company reported ($0.16) earnings per share for the quarter. The firm had revenue of $0.01 million during the quarter. On average, sell-side analysts predict that Inventiva S.A. Sponsored ADR will post -0.8 earnings per share for the current year.
Institutional Investors Weigh In On Inventiva
Large investors have recently modified their holdings of the stock. UBS Group AG grew its stake in shares of Inventiva by 28,881.6% in the 4th quarter. UBS Group AG now owns 2,643,702 shares of the company’s stock valued at $12,293,000 after purchasing an additional 2,634,580 shares during the period. Simplify Asset Management Inc. bought a new stake in shares of Inventiva in the 4th quarter valued at approximately $1,570,000. Wealth Enhancement Advisory Services LLC grew its stake in shares of Inventiva by 55.6% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 25,770 shares of the company’s stock valued at $142,000 after purchasing an additional 9,212 shares during the period. NewEdge Advisors LLC bought a new stake in shares of Inventiva in the 3rd quarter valued at approximately $116,000. Finally, Cerity Partners LLC bought a new stake in shares of Inventiva in the 4th quarter valued at approximately $93,000. 19.06% of the stock is currently owned by institutional investors.
About Inventiva
Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.
The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.
Featured Articles
- Five stocks we like better than Inventiva
- MarketBeat Week in Review – 06/01 – 06/05
- AI Server Earnings: Wall Street Sees One Clear Standout
- Navitas: NVIDIA’s AI Power Broker?
- A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below
Receive News & Ratings for Inventiva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inventiva and related companies with MarketBeat.com's FREE daily email newsletter.
